SAN DIEGO, Oct. 16, 2013 /PRNewswire/ -- ViaCyte, Inc., a leading regenerative medicine company developing a transformative cell therapy for the treatment of diabetes, today announced that it will present a scientific overview at the JDRF 8th Annual T1D Global Path to a Cure Symposium on Saturday, October 19, 2013, at 2:10 PM PT in Redmond, Washington. The presentation will be given by Eugene Brandon, Ph.D., Director of Strategic Relations & Project Management at ViaCyte.
ViaCyte will review its development activity related to VC-01™ combination product, its stem cell-derived, cell therapy product that the company believes could transform the way patients with Type 1 diabetes manage their disease. The product is comprised of pancreatic progenitor cells contained in a proprietary device that is designed to be inserted under the skin. Upon implant, the product is expected to vascularize as the cells further differentiate to islet-like structures that generate insulin and other expected regulatory factors in response to blood glucose levels, essentially providing patients with a replacement for the cells lost as a result of the disease.
The company has reviewed the VC-01™ combination product development plans with regulatory authorities at the US Food and Drug Agency and Health Canada. Pending regulatory authority review of its planned application to conduct a clinical trial, the company is planning to initiate clinical development in patients with Type 1 diabetes in the first half of next year. The company has received substantial funding for the development of the product from the California Institute for Regenerative Medicine and JDRF.
President and CEO, Paul Laikind, Ph.D. said, "We are very excited about the progress we have made towards what could amount to essentially a cure for patients with Type 1 diabetes. We look forward to reviewing our work and describing our plans for clinical development."
ViaCyte, a private company that has emerged as a leader in the field of regenerative medicine, is currently focused on developing a novel cell therapy for the treatment of diabetes. The Company's lead product is based on the production of pancreatic progenitors derived from human pluripotent stem cells. These cells are implanted in a durable and retrievable encapsulation device called the Encaptra® drug delivery system. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. ViaCyte's goal for this potentially transformative diabetes product is long term insulin independence without immune suppression, and without risk of hypoglycemia and other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by CIRM and JDRF.
SOURCE ViaCyte, Inc.